Axogen, Inc. (AXGN) fair value analysis
Nasdaq · Updated 2026-10-19
AXGN price how computed
Valuation status
Awaiting full valuationAXGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $34.62
- Sector
- Healthcare
- 12-month range
- $17.77–$51.73
- Market cap
- $2.03B
- From 52-week high
- -33.1%
- Shares outstanding
- 58.7M
- Rank in Healthcare by quality score
- #34 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Axogen, Inc. is a healthcare company that develops and markets surgical solutions for peripheral nerve injuries, including nerve grafts and related products used in surgical repair procedures. The company operates primarily in the United States and serves hospitals, surgical centers, and healthcare providers that treat patients requiring nerve reconstruction.
AXGN currently ranks #34 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.03B
- P/E (trailing)
- 151x
- Revenue (TTM)
- $251M
- Net margin
- -13.4%
- EPS (TTM)
- $0.23
- Gross margin
- 72.7%
- Debt / equity
- 0.08
- Revenue growth (3-yr avg)
- 23.0%
- Shares outstanding
- 58.7M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Stable
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 20 · oversold
- 50-day average
- $44.41
- 200-day average
- $39.14
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2010-01-27)
Earnings how computed
- Next earnings report
- 2026-10-28 (pre-market)
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+25.0%)
2026-03 ▬ met (0.0%)
2025-12 ▲ beat (+19.5%)
2025-09 ▲ beat (+71.4%)
2025-06 ▲ beat (+100.0%)
2025-03 ▼ miss (-200.0%)
2024-12 ▲ beat (+133.3%)
2024-09 ▲ beat (+250.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 0 hold · 0 sell (10 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $53.5
- Target vs last price
- +54.5%
What our data shows for AXGN
- Our model validated 4 trailing price-to-earnings windows for AXGN, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $17.77–$51.73.
- The 14-day relative strength index sits at an oversold 20.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- AXGN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent AXGN news
TickrTrends' derived news-sentiment signal for AXGN is currently leaning positive, computed from recent coverage.
- Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 (manilatimes.net, 2026-10-14)
- AXGN Initiates Coverage On by B of A Securities -- Rating Set to Buy (gurufocus.com, 2026-10-12)
- Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair (manilatimes.net, 2026-10-01)
More AXGN news
- AXGN Maintained by Truist Securities -- Price Target Lowered to $53 (gurufocus.com, 2026-10-01)
What people are saying
Follow the AXGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — AXGN's Relative Strength Index moved into oversold territory this week, shifting from a neutral zone reading in the prior week. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full analysis. This technical indicator change suggests the stock may be experiencing downward momentum from a momentum-trading perspective.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — # TickrTrends Indicator Summary for AXGN AXGN's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the stock's momentum trajectory relative to its longer-term moving averages. The valuation assessment for the healthcare company remains pending a complete valuation analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AXGN stock undervalued?
AXGN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is AXGN's TickrTrends verdict?
AXGN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does AXGN compare to other Healthcare stocks?
AXGN ranks #34 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is AXGN overbought or oversold?
AXGN's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
Does AXGN pay a dividend?
AXGN has paid no dividend in the last twelve months; its last ex-dividend date on file was 2010-01-27.
When does AXGN report earnings next?
AXGN's next earnings report is scheduled for 2026-10-28 (pre-market), per the published earnings calendar.
Does AXGN usually beat earnings estimates?
Over its last 8 reported quarters AXGN beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AXGN?
Of 10 analysts covering AXGN, 10 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $53.5 (+54.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.